Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI363 + fruquintinib
- Development stage
- Phase 1
- Lead developer
- Suzhou Innovent Biologics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
IBI363 + fruquintinib is a combination therapy currently being evaluated in Phase 1 clinical trials for the treatment of advanced colorectal cancer, specifically targeting patients with microsatellite stable (MSS) or proficient mismatch repair (pMMR) tumors. IBI363 is a first-in-class bispecific antibody fusion protein that simultaneously blocks the Programmed Cell Death Protein 1 (PD-1) pathway and provides biased Interleukin-2 (IL-2) signaling. By targeting IL-2α (CD25), IBI363 is designed to selectively stimulate tumor-specific T cells while minimizing the systemic toxicity typically associated with high-dose IL-2 therapy. Fruquintinib (also referred to as furuitinib) is a highly selective and potent small molecule tyrosine kinase inhibitor that targets Vascular Endothelial Growth Factor Receptors (VEGFR) 1, 2, and 3, thereby inhibiting tumor angiogenesis. The combination is intended to convert immunologically "cold" tumors into "hot" tumors by combining immune checkpoint blockade and cytokine stimulation with anti-angiogenic effects.
- Other names
- IBI363 + furuitinibIBI363 plus fruquintinibIBI-363 plus fruquintinibIBI 363 plus fruquintinibIBI363 plus furuitinibIBI-363 plus furuitinibIBI 363 plus furuitinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)IL2RA (Interleukin-2 receptor alpha subunit)IL2RB (IL-2 receptor beta chain)IL2RG (Interleukin-2 receptor gamma subunit)PDCD1 (Programmed cell death protein 1 receptor)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on IBI363 + fruquintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI363 + fruquintinib.